HS resource center

Pearls for treating hidradenitis suppurative in kidsHidradenitis suppurativa can impact children and teens physically and emotionally. A dermatologist explains potential differences between pediatric and adult HS.
Creating the virtual HS multispecialty clinicExpert dermatologist describes how to create the virtual multispecialty clinic to address the complex needs of hidradenitis suppurativa.
Nonablative technologies and the HS patientNonablative lasers, which are essentially modified hair removal lasers, offer treatment benefits for HS patients with stage 1 or stage 2 disease, according to dermatologist.
Combined therapy targets inflammationResearchers treated a small cohort with two anti-inflammatory drugs and saw a significant improvement in clinical manifestations of disease. Further data showed the approach safely maintained results.
HS treatment requires multipronged approach
HS treatment requires multipronged approachEvidence supports combined treatments to target the many factors tied to hidradenitis suppurativa.
Hidradenitis suppurativa misunderstood and underdiagnosedMisconceptions about hidradenitis suppurativa (HS) prevent dermatologists and other clinicians from properly diagnosing and treating what one expert says is a “crippling disease.”
Hidradenitis Suppurativa therapy options progressing
Hidradenitis Suppurativa therapy options progressingMany physicians miss diagnosing hidradenitis suppurativa upon first presentation. Recognizing key traits may help physicians diagnose and begin treatment of the disease earlier.
TNF Inhibitors Prove EffectiveTNF inhibitors shown to be effective in improving the clinical symptoms of moderate to severe hidradenitis suppurativa, representing an exciting therapeutic option for this challenging disease.
Infection-causing bacteria found in hidradenitis suppurativa lesionsBacteria responsible for causing skin and soft tissue infections has been found in hidradenitis suppurativa lesions, results of a recent study indicate.
Early results encouraging in study of adalimumab for hidradenitis suppurativaNew results from a phase-3 study demonstrating the effect of Humira (adalimumab, AbbVie) in treating moderate-to-severe hidradenitis suppurativa (HS) may lead to worldwide regulatory filings for expanded use of the drug.